San Antonio Breast Cancer Symposium | Conference

Sentinel Lymph Node Surgery After Chemotherapy Shows Accuracy in Nodal Staging in Breast Cancer

December 5th 2012

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

December 5th 2012

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Dr. Boughey on Reducing False Negatives in SLN Surgery

December 5th 2012

Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

December 5th 2012

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

Dr. Hope Rugo Previews the 2012 SABCS Program

November 13th 2012

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

December 9th 2011

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Photos From the 2011 San Antonio Breast Cancer Symposium

December 9th 2011

A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

December 9th 2011

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

December 9th 2011

Dr. JosÃ© Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

December 9th 2011

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

December 9th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

December 9th 2011

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

December 8th 2011

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

December 8th 2011

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

December 7th 2011

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

December 7th 2011

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial

New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ

December 7th 2011

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Dr. Solin Discusses the DCIS Score Recurrence Test

December 7th 2011

Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test